Quality Expectations for Drugs and Biologics during Early Development: Phase 3 and NDA

Speaker

Instructor: Steven S Kuwahara
Product ID: 701011

Location
  • Duration: 75 Min
This presentation will discuss the quality-related activities that are expected for Phase 3 products used in clinical studies and the needs of the key demonstration lots that will be submitted with the NDA. This presentation will be aimed at helping Regulatory, Quality Assurance and Quality Control personnel to understand the varying levels of quality activities that accompany early stages of Product development.
RECORDED TRAINING
Last Recorded Date: Nov-2008

 

$299.00
1 Person Unlimited viewing for 6 month info Recorded Link and Ref. material will be available in My CO Section
(For multiple locations contact Customer Care)

$500.00
Downloadable file is for usage in one location only. info Downloadable link along with the materials will be emailed within 2 business days
(For multiple locations contact Customer Care)

 

 

Customer Care

Fax: +1-650-362-2367

Email: [email protected]

Read Frequently Asked Questions

 

Even in Phase 3 clinical studies the requirements for the CMC section will not be identical as the requirements for marketed products. However it is important to set the stage for the routine production of a marketed product. The nature and extent of these activities depend on the type of drug and difficulties encountered in any scale-up processes. This presentation will discuss the quality-related activities that are expected for Phase 3 products used in clinical studies and the needs of the key demonstration lots that will be submitted with the NDA. Emphasis will be placed on the transition into full GMP work as clinical trials conclude. The requirements for NDAs (or BLAs) will be discussed. The quality elements for CMCs that are needed for Phase 3 clinical studies will be presented.

Areas Covered in the seminar:

  • We will discuss the key guidance documents that will help to guide a company in the later stages of clinical trials and in the preparation of their NDA.
  • Letting FDA help you in making your submission.
  • What you need to do to prepare for Phase 3 and the NDA.
  • Concerns if you are preparing a BLA.
  • What to do about QC studies such as instrument qualification, method validation, and process validation.
  • What do you need for the CMC section?
  • Use of the Common Technical Document (CTD) to determine activities.

Who will benefit:

This presentation will be aimed at helping Regulatory, Quality Assurance and Quality Control personnel to understand the varying levels of quality activities that accompany early stages of Product development.

  • Regulatory Affairs personnel who coordinate activities for the CMC sections of submissions
  • QA/QC personnel who need to plan work
  • R & D personnel who will contribute data to CMC sections
  • Project managers for product development studies
  • Quality systems auditors
  • Consultants

Instructor Profile

Steven S. Kuwahara, Ph.D. is the founder and Principal of GXP BioTechnology LLC, a consulting firm that works in the areas covered by the GLP and GMP of drugs, biologics, and nutraceuticals. Steve has over 30 years of experience in supervising quality control laboratories, including an animal testing facility, and in performing GLP and GMP audits of internal and external testing laboratories . He has participated in the product development process for small molecule drugs and biologics, and has prepared or reviewed many CMC sections.

Follow us :

 

 

Refund Policy

Our refund policy is governed by individual products and services refund policy mentioned against each of offerings. However in absence of specific refund policy of an offering below refund policy will be effective.
Registrants may cancel up to two working days prior to the course start date and will receive a letter of credit to be used towards a future course up to one year from date of issuance. ComplianceOnline would process/provide refund if the Live Webinar has been cancelled. The attendee could choose between the recorded version of the webinar or refund for any cancelled webinar. Refunds will not be given to participants who do not show up for the webinar. On-Demand Recordings can be requested in exchange. Webinar may be cancelled due to lack of enrolment or unavoidable factors. Registrants will be notified 24hours in advance if a cancellation occurs. Substitutions can happen any time. On-Demand Recording purchases will not be refunded as it is available for immediate streaming. However if you are not able to view the webinar or you have any concern about the content of the webinar please contact us at below email or by call mentioning your feedback for resolution of the matter. We respect feedback/opinions of our customers which enables us to improve our products and services. To contact us please email [email protected] call +1-888-717-2436 (Toll Free).

 

 

+1-888-717-2436

6201 America Center Drive Suite 240, San Jose, CA 95002, USA

Follow Us

facebook twitter linkedin youtube

 

Copyright © 2023 ComplianceOnline.com MetricStream
Our Policies: Terms of use | Privacy

PAYMENT METHOD: 100% Secure Transaction

payment method